Table 9.

Optimal candidates for studies evaluating graft-versus-tumor (GVT) effect in solid tumors

  • Good performance status (ECOG 0-1)

  • Younger patient age (i.e., < 65 years)

  • Life expectancy of at least 6 months

  • Absence of central nervous system (CNS) metastatic disease

  • Tumor volume small with slow proliferative kinetics

  • Tumor tissue of origin a target for acute or chronic graft-versus-host disease

  • In vitro or clinical evidence that tumor is susceptible to immune-attack

 

  • Good performance status (ECOG 0-1)

  • Younger patient age (i.e., < 65 years)

  • Life expectancy of at least 6 months

  • Absence of central nervous system (CNS) metastatic disease

  • Tumor volume small with slow proliferative kinetics

  • Tumor tissue of origin a target for acute or chronic graft-versus-host disease

  • In vitro or clinical evidence that tumor is susceptible to immune-attack

 
View Large
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal